摘要
目的研究miR-455-3p在非小细胞肺癌中的生物学功能及其机制。方法通过实时荧光定量PCR和蛋白免疫印迹分析癌旁组织和癌组织中miR-455-3p和组蛋白脱乙酰基酶2(HDAC2)的表达水平。将A549细胞分为4组:miR NC组、miR-455-3p mimics组、si NC组和si HDAC2组。通过MTT实验分析细胞的增殖能力,流式细胞仪分析细胞的凋亡率,蛋白免疫印迹分析HDAC2和Ki-67的表达水平,通过双荧光素酶报告基因实验和生物信息学分析miR-455-3p的靶点。结果miR-455-3p在非小细胞肺癌组织中低表达而HDAC2高表达(癌旁组织和癌组织中miR-455-3p分别为1.03±0.02、0.46±0.01;癌旁组织和癌组织中HDAC2分别为0.17±0.01、0.43±0.02,P<0.05);过表达miR-455-3p或者抑制HDAC2后都能抑制A549细胞增殖和侵袭能力,并诱导A549细胞凋亡;miR-455-3p能够靶向抑制HDAC2的表达(癌旁组织和癌组织分别为1.01±0.03、0.21±0.01;P<0.05)。结论miR-455-3p在非小细胞肺癌组织中低表达而HDAC2高表达,此外,miR-455-3p通过靶向调节HDAC2进而抑制非小细胞肺癌的体外增殖。
Objective To investigate the biological function and mechanism of miR-455-3p in non-small cell lung cancer.Methods The expression levels of miR-455-3p and histone deacetylase 2(HDAC2)in adjacent tissues and cancer tissues were analyzed by real-time fluorescent quantitative PCR and Western blot.The A549 cells were divided into four groups:miR NC group,Mir-455-3p mimics group,si NC group and si HDAC2 group.The cell proliferation ability was analyzed by MTT assay,the apoptosis rate was analyzed by flow cytometry,the expression levels of HDAC2 and Ki-67 were analyzed by Western blot,and the target of miR-455-3p was analyzed by dual luciferase reporter gene assay and bioinformatics.Results The expression of miR-455-3p was low(1.03±0.02 and0.46±0.01 in adjacent tissues and cancer tissues,repectively,P<0.05)and HDAC2 was high(0.17±0.01 and 0.43±0.02 in adjacent tissues and cancer tissues,respectively,P<0.05)in NSCLC tissues.Overexpression of miR-455-3p or inhibition of HDAC2 inhibited the proliferation and invasion of A549 cells,and induced apoptosis of A549 cells.miR-455-3p can target and inhibit the expression of HDAC2(1.01±0.03 and 0.21±0.01 in adjacent tissues and cancer tissues,respectively,P<0.05).Conclusion The miR-455-3p is lowly expressed and HDAC2 is highly expressed in NSCLC tissues.In addition,miR-455-3p inhibits the proliferation of NSCLC in vitro by targeting HDAC2.
作者
陈娟
魏丹
吕格妮
谢万会
王耀元
张文哲
王恒瑜
董济民
CHEN Juan;WEI Dan;LV Ge-ni;XIE Wan-hui;WANG Yao-yuan;ZHANG Wen-zhe;WANG Heng-yu;DONG Ji-min(Department of Respiratory Medicine,No.215 Hospital of Shaanxi Nuclear Industry,Xianyang 712099;Department of Nosocomial Infection Management,No.215 Hospital of Shaanxi Nuclear Industry,Xianyang 712099;Department of Oncology,Xi'an Central Hospital,Xi'an 710000)
出处
《解剖学研究》
CAS
2023年第5期454-459,共6页
Anatomy Research
基金
陕西省科技计划项目(2016SF-318)。
